These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 20799460

  • 1. New regulatory documents and procedures. I: Guideline on clinical trials of SIT products, European Pharmacopoeia, and note for guidance on allergen products.
    Pini C.
    Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess; 2009; 96():187-90; discussion 191-2. PubMed ID: 20799460
    [No Abstract] [Full Text] [Related]

  • 2. Registration trials for specific immunotherapy in Europe: advanced guidance from the new European Medical Agency guideline.
    Gödicke V, Hundt F.
    Allergy; 2010 Dec; 65(12):1499-505. PubMed ID: 20608914
    [Abstract] [Full Text] [Related]

  • 3. Clinical trials with recombinant allergens--a regulatory perspective.
    Elferink AF.
    Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess; 2009 Dec; 96():266-7; discussion 267-9. PubMed ID: 20799470
    [No Abstract] [Full Text] [Related]

  • 4. Regulatory environment for allergen-specific immunotherapy.
    Kaul S, May S, Lüttkopf D, Vieths S.
    Allergy; 2011 Jun; 66(6):753-64. PubMed ID: 21288251
    [Abstract] [Full Text] [Related]

  • 5. Pediatric investigation plans for specific immunotherapy: Questionable contributions to childhood health.
    Rose K, Kopp MV.
    Pediatr Allergy Immunol; 2015 Dec; 26(8):695-701. PubMed ID: 26495999
    [Abstract] [Full Text] [Related]

  • 6. The regulatory system in europe with special emphasis on allergen products.
    Lorenz AR, Luttkopf D, Seitz R, Vieths S.
    Int Arch Allergy Immunol; 2008 Dec; 147(4):263-75. PubMed ID: 18648190
    [Abstract] [Full Text] [Related]

  • 7. [Allergens for specific immunotherapy: authorization and quality criteria of the Paul-Ehrlich-Institut].
    May S, Kaul S, Schröder C, Vieths S.
    Hautarzt; 2006 Oct; 57(10):867-74. PubMed ID: 16977441
    [Abstract] [Full Text] [Related]

  • 8. Regulatory Requirements for the Quality of Allergen Products for Allergen Immunotherapy of Food Allergy.
    Englert L, Mahler V, Bonertz A.
    Curr Allergy Asthma Rep; 2021 May 10; 21(5):32. PubMed ID: 33970347
    [Abstract] [Full Text] [Related]

  • 9. Standardisation of allergens in Europe.
    Sjöholm I.
    Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 1997 May 10; (91):107-10. PubMed ID: 9383897
    [Abstract] [Full Text] [Related]

  • 10. Are we following practice parameter guidelines on allergen immunotherapy?
    Chacko T.
    Ann Allergy Asthma Immunol; 2008 Feb 10; 100(2):178. PubMed ID: 18320926
    [No Abstract] [Full Text] [Related]

  • 11. European Academy of Allergy and Clinical Immunology task force report on 'dose-response relationship in allergen-specific immunotherapy'.
    Calderón MA, Larenas D, Kleine-Tebbe J, Jacobsen L, Passalacqua G, Eng PA, Varga EM, Valovirta E, Moreno C, Malling HJ, Alvarez-Cuesta E, Durham S, Demoly P.
    Allergy; 2011 Oct 10; 66(10):1345-59. PubMed ID: 21707645
    [Abstract] [Full Text] [Related]

  • 12. New guidance on the regulation of allergen products: key aspects and outcomes.
    Bonertz A, Mahler V, Vieths S.
    Curr Opin Allergy Clin Immunol; 2020 Dec 10; 20(6):624-630. PubMed ID: 32826400
    [Abstract] [Full Text] [Related]

  • 13. Regulatory aspects of allergen products for immunotherapy--considerations from the viewpoint of manufacturers.
    Kroon AM.
    Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 2006 Dec 10; (95):49-58; discussion 58-9. PubMed ID: 17393722
    [Abstract] [Full Text] [Related]

  • 14. Guidance for the regulatory status of allergen extracts in clinical trials.
    Diamant Z, van Maaren M, van Wijk RG, Brouwers JR, Pieterse H.
    Eur Respir J; 2015 Oct 10; 46(4):1223-5. PubMed ID: 26424525
    [No Abstract] [Full Text] [Related]

  • 15. Proposals for harmonization of allergens regulation in the European Union.
    Timón M.
    Allergol Immunopathol (Madr); 2017 Dec 10; 45 Suppl 1():1-3. PubMed ID: 29108764
    [Abstract] [Full Text] [Related]

  • 16. Comparison of allergen immunotherapy practice patterns in the United States and Europe.
    Cox L, Jacobsen L.
    Ann Allergy Asthma Immunol; 2009 Dec 10; 103(6):451-59; quiz 459-61, 495. PubMed ID: 20084837
    [Abstract] [Full Text] [Related]

  • 17. European Union guidance on the quality, safety and efficacy of DNA vaccines and regulatory requirements.
    Robertson JS, Cichutek K.
    Dev Biol (Basel); 2000 Dec 10; 104():53-6. PubMed ID: 11713824
    [Abstract] [Full Text] [Related]

  • 18. Close collaboration between academia, industry and drug regulators is required in the development of allergen products for specific immunotherapy in children.
    Eichler I, Soriano ES.
    Allergy; 2011 Aug 10; 66(8):999-1004. PubMed ID: 21426358
    [Abstract] [Full Text] [Related]

  • 19. New regulatory rules for clinical trials in the United States and the European Union: key points and comparisons.
    Miossec M, Miossec P.
    Arthritis Rheum; 2006 Dec 10; 54(12):3735-40. PubMed ID: 17133535
    [No Abstract] [Full Text] [Related]

  • 20. [New administration routes for immunotherapy].
    Martorell Aragonés A.
    Allergol Immunopathol (Madr); 2000 Dec 10; 28(3):93-102. PubMed ID: 10867377
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.